
Chinese biopharmaceutical company founded in 2017 in Wuxi, Jiangsu as a joint venture backed by AstraZeneca and the Advanced Manufacturing Industry Investment Fund of China, and listed on the Shanghai STAR Market under code 688192. Discovers and develops small molecule and biologic medicines for cancer and immunological disease, with research operations in Shanghai and Wuxi and a global clinical development footprint. Its approved and late stage products include the EGFR exon 20 insertion inhibitor sunvozertinib and the JAK1 and Aurora A inhibitor golidocitinib for peripheral T-cell lymphoma.
평가 남기기